Hayashi T, Usui M, Nishioka J, Zhang Z X, Suzuki K
Department of Molecular Pathobiology, Mie University School of Medicine, Tsu-city, Mie 514, Japan.
Biochem J. 1998 Jun 1;332 ( Pt 2)(Pt 2):573-82. doi: 10.1042/bj3320573.
Protein C inhibitor (PCI) is the plasma inhibitor of activated protein C, which is the main protease of the anticoagulant protein C pathway. In this study the transcriptional regulation of human PCI gene in the human hepatoma cell line, HepG2, was characterized by evaluating the transient expression of a luciferase reporter gene. The 5' flanking region (residues -1587 to +2) of the PCI gene showed an adequate transcriptional activity, the maximum transcriptional activity being in a region between residues -452 and -94, which contains an Sp1-binding site, two AP2-binding sites and an inverted AP2-binding site. Transient expression assays with various deletion mutants and site-directed mutants showed that the Sp1-binding site (residues -302 to -294) has a potent promoter activity and that the upstream AP2-binding site (residues -350 to -343) has a potent enhancer activity; no activity was detected in the inverted (residues -413 to -404) and downstream (residues -136 to -127) AP2-binding sites. In addition, a region of the PCI gene (residues -452 to -414) containing the STATx-binding site, the A-activator (AA)-binding site, and the interferon alpha (IFN-alpha) response element, and another region of the PCI gene (residues -176 to -147) containing the GATA-1 and the IFN-gamma response element showed potent silencer activities. Gel mobility-shift assays with various DNA fragments indicated that the Sp1-binding site, the upstream AP2-binding site, the AA-binding site and the IFN-gamma response element interact with nuclear protein(s) of HepG2 cells. These findings suggest that the Sp1-binding site is the promoter, the AP2-binding site (residues -350 to -343) the enhancer, and both the AA-binding site and the IFN-gamma response element are the silencers of human PCI gene expression in HepG2 cells.
蛋白C抑制剂(PCI)是活化蛋白C的血浆抑制剂,活化蛋白C是抗凝蛋白C途径的主要蛋白酶。在本研究中,通过评估荧光素酶报告基因的瞬时表达来表征人肝癌细胞系HepG2中人PCI基因的转录调控。PCI基因的5'侧翼区域(-1587至+2位残基)显示出足够的转录活性,最大转录活性位于-452至-94位残基之间的区域,该区域包含一个Sp1结合位点、两个AP2结合位点和一个反向AP2结合位点。对各种缺失突变体和定点突变体进行的瞬时表达分析表明,Sp1结合位点(-302至-294位残基)具有强大的启动子活性,上游AP2结合位点(-350至-343位残基)具有强大的增强子活性;在反向(-413至-404位残基)和下游(-136至-127位残基)AP2结合位点未检测到活性。此外,PCI基因的一个包含STATx结合位点、A激活剂(AA)结合位点和干扰素α(IFN-α)反应元件的区域(-452至-414位残基),以及另一个包含GATA-1和IFN-γ反应元件的PCI基因区域(-176至-147位残基)显示出强大的沉默子活性。用各种DNA片段进行的凝胶迁移率变动分析表明,Sp1结合位点、上游AP2结合位点、AA结合位点和IFN-γ反应元件与HepG2细胞的核蛋白相互作用。这些发现表明,Sp1结合位点是启动子,AP2结合位点(-350至-343位残基)是增强子,AA结合位点和IFN-γ反应元件都是HepG2细胞中人PCI基因表达的沉默子。